2022
DOI: 10.1002/cncr.34168
|View full text |Cite
|
Sign up to set email alerts
|

Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility

Abstract: This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 57 publications
0
7
0
Order By: Relevance
“…Defining true progression is important, particularly in advanced NSCLC, covering a limited numbers of treatment lines. Yet, a clear definition of a substantial ctDNA increase has not been clarified and studies have different methods of reporting including different definitions ( 29 ). By comparing 95% CI intervals of subsequent measurements, we found a substantial increase in 74% of patients.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Defining true progression is important, particularly in advanced NSCLC, covering a limited numbers of treatment lines. Yet, a clear definition of a substantial ctDNA increase has not been clarified and studies have different methods of reporting including different definitions ( 29 ). By comparing 95% CI intervals of subsequent measurements, we found a substantial increase in 74% of patients.…”
Section: Discussionmentioning
confidence: 99%
“…Yet, the optimal strategy for ctDNA measurements have not been defined, which includes optimizing methods of detection and defining and validating thresholds for ctDNA increases/decreases as surrogate markers of treatment response (ctDNA RECIST; ref. 29 ). Further analytic and clinical validation is needed, before moving to the next step of investigating clinical utility ( 52 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“… 5 Last year, Thomsen et al underscored the lack of evidence of clinical utility as the reason that ctDNA assays should not yet be routinely used for monitoring patients with metastatic cancer. 6 …”
Section: Commentarymentioning
confidence: 99%
“…In recent articles published in Cancer, the Journal of Clinical Oncology, JCO Precision Oncology and elsewhere, experts have considered the challenges in defining “clinical utility.” 6 8 But clinical utility is “rarely easily quantified” and is “frequently a matter of judgment.” 7 …”
Section: Commentarymentioning
confidence: 99%